MK-677 (Ibutamoren): History, Development, and Mechanism of Action

The Problem MK-677 Was Designed to Solve

Before MK-677 existed, clinicians who wanted to raise growth hormone levels had exactly one reliable option: injectable recombinant human GH (rhGH). That worked. It also cost thousands of dollars per month, required daily subcutaneous injections, and bypassed the body's own pulsatile GH regulation entirely 1.

GH declines with age. By the sixth decade, 24-hour integrated GH concentrations fall to roughly one-third of young-adult values 2. This age-related decline, sometimes called somatopause, correlates with loss of lean mass, increased adiposity, reduced bone mineral density, and impaired sleep quality. Replacing GH exogenously raised obvious questions: could a drug stimulate the pituitary to release its own GH on a normal pulsatile schedule? And could that drug be taken by mouth?

The answer to both questions turned out to be yes. The compound was MK-677.

Merck's Discovery Program: From Peptide Leads to an Oral Molecule

The story begins in the late 1980s at Merck Research Laboratories in Rahway, New Jersey. A medicinal chemistry team led by Art Patchett and Roy Smith set out to find small molecules that could trigger GH release from the pituitary without requiring injection 3.

Earlier work by Cyril Bowers at Tulane University had demonstrated that short synthetic peptides (GH-releasing peptides, or GHRPs) could stimulate GH secretion through a receptor distinct from the one used by growth hormone-releasing hormone (GHRH). The receptor was unknown at the time. Bowers' peptides proved the concept but were not orally bioavailable, and they degraded rapidly in plasma.

Patchett's group at Merck screened thousands of non-peptide compounds against pituitary cell lines expressing this orphan receptor. The effort produced a benzolactam series with oral activity. MK-677 (ibutamoren mesylate) emerged as the lead clinical candidate: a spiro-piperidine compound with high oral bioavailability, a plasma half-life of approximately 5 hours, and the ability to raise GH in a dose-dependent manner after a single oral dose 3.

As Patchett and colleagues described in the Proceedings of the National Academy of Sciences in 1995, MK-677 "represents the first example of a nonpeptidyl substance with potent, long-lasting oral activity as a GH secretagogue in humans" 3. That paper marked the compound's formal introduction to the research community.

Identifying the Target: Cloning of the GHS-R1a Receptor

A parallel Merck effort, published in Science in 1996 by Howard, Feighner, and colleagues, used MK-677 itself as a pharmacological tool to clone the receptor responsible for GHRP-mediated GH release 4. The team identified a novel G-protein-coupled receptor they designated GHS-R1a (growth hormone secretagogue receptor type 1a).

This was a landmark. Four years later, Kojima et al. identified ghrelin as the endogenous ligand for GHS-R1a, finally explaining why a pituitary-targeted synthetic compound also increased appetite. MK-677 is, in pharmacological terms, a ghrelin mimetic. It binds the same receptor ghrelin binds. But it was synthesized before ghrelin was even discovered.

The receptor is expressed in the hypothalamus (arcuate and ventromedial nuclei), the anterior pituitary, and in peripheral tissues including the pancreas and gut. This distribution explains both the GH-releasing effect and the side-effect profile: appetite stimulation, mild fluid retention, and dose-dependent changes in fasting glucose 4.

How MK-677 Works: Mechanism at the Molecular Level

MK-677 binds GHS-R1a with high affinity and activates a Gq/11-coupled signaling cascade. In somatotroph cells of the anterior pituitary, this triggers phospholipase C activation, inositol trisphosphate (IP3) generation, intracellular calcium release, and ultimately GH exocytosis 4.

Three features distinguish this mechanism from exogenous GH injection.

First, MK-677 amplifies physiological GH pulses rather than creating a flat pharmacological concentration. The compound increases both pulse amplitude and mean 24-hour GH concentrations while preserving the pulsatile secretion pattern 2.

Second, it acts synergistically with GHRH. When endogenous GHRH reaches the pituitary, the presence of MK-677 at GHS-R1a lowers the threshold for somatotroph activation. This means the largest GH pulses occur during sleep, when GHRH tone is highest. Copinschi et al. demonstrated in 1997 that MK-677 at 25 mg increased nocturnal GH pulse amplitude by 50% and prolonged the duration of stage IV (slow-wave) sleep by approximately 20% in young healthy males 5.

Third, negative feedback is preserved. Somatostatin still suppresses GH release, and IGF-1 feedback loops remain intact. This is why MK-677 does not produce the supraphysiological IGF-1 levels sometimes seen with high-dose injectable GH.

The downstream effect is a sustained rise in circulating IGF-1. Across multiple studies, 25 mg daily raised IGF-1 by 40 to 60% above baseline within two weeks, and this increase persisted for as long as subjects continued taking the compound 2 6.

The Chapman Dose-Finding Study (1996)

The first controlled dose-escalation trial in humans was published by Chapman et al. in the Journal of Clinical Endocrinology & Metabolism in 1996. This crossover study enrolled healthy young men and tested single oral doses of MK-677 at 5, 10, 25, and 50 mg 1.

Results were clear. At 25 mg, mean serum GH AUC increased approximately 6-fold over placebo during the 8-hour post-dose window. IGF-1 rose significantly within 48 hours. The 50 mg dose did not produce substantially greater GH output than 25 mg, suggesting a ceiling effect at the pituitary level 1.

Chapman described the compound's profile as "unique among GH secretagogues for its oral bioavailability and sustained duration of GH release" 1. The 25 mg once-daily dose became the standard for all subsequent trials.

Side effects at this stage were mild. Appetite increased in most subjects within 1 to 2 hours of dosing, consistent with ghrelin receptor activation in the hypothalamus. A few subjects reported transient lower-extremity edema. No serious adverse events occurred.

The Murphy Key Study (1998)

The trial most frequently cited in MK-677 literature is Murphy et al., published in JCEM in 1998 2. This study enrolled older adults (ages 64 to 81) and administered MK-677 at 25 mg or 2 mg daily for up to two 14-day treatment periods separated by a washout.

At 25 mg, 24-hour mean GH concentration increased to levels comparable to those seen in healthy young adults. IGF-1 rose by an average of 52% from baseline. The pulsatile pattern of GH release was maintained, and there was no evidence of GHS-R1a desensitization over the two-week dosing period 2.

Cortisol showed a transient increase in the first week but normalized by day 14. Prolactin rose modestly. Thyroid hormones remained unchanged. These findings indicated that MK-677 was relatively selective for the somatotroph axis, with only minor off-target hormonal effects.

The Murphy trial established two points that shaped all later MK-677 research: the compound worked in elderly subjects (the population most affected by somatopause), and it worked consistently over repeated dosing without tachyphylaxis.

The Nass Long-Duration Trial (2008)

The longest controlled MK-677 study was published a decade later by Nass et al. in the Annals of Internal Medicine. This randomized, double-blind, placebo-controlled trial gave MK-677 25 mg or placebo nightly to 65 healthy older adults (ages 60 to 81) for two full years 6.

GH and IGF-1 increased to young-adult levels and stayed there for the full 24 months. No tachyphylaxis developed. Body weight increased by a mean of 1.3 kg in the MK-677 group versus 0.6 kg in the placebo group, consistent with fluid retention and mild appetite stimulation 6.

The critical finding was a safety signal. Fasting blood glucose rose by approximately 0.3 mmol/L in the MK-677 group, and fasting insulin increased by 1.4 μIU/mL. HbA1c did not change significantly, but the trend toward insulin resistance was consistent across multiple prior studies. In subjects with pre-existing impaired glucose tolerance, glucose rose to diabetic thresholds in some cases 6.

Nass et al. concluded that "although MK-677 effectively restores GH and IGF-1 to youthful concentrations, the observed decrease in insulin sensitivity raises concern about long-term cardiometabolic safety" 6.

This trial likely contributed to Merck's decision not to pursue Phase III development. No Phase III trial for MK-677 was ever registered.

Why MK-677 Never Reached FDA Approval

Several factors converged. The insulin resistance signal, while modest, was consistent. Anti-aging was not (and still is not) an FDA-approvable indication; the agency requires a disease endpoint. And Merck's commercial calculus shifted. By the mid-2000s, injectable GH was well-established for adult GH deficiency, and the incremental benefit of an oral secretagogue over injection was unclear if the primary use case lacked regulatory backing.

No new drug application (NDA) for ibutamoren was ever submitted to the FDA 7. The compound remains classified as an investigational drug. The FDA has issued repeated warnings about MK-677 appearing in gray-market supplements and "research chemical" sales, noting that products marketed as dietary supplements containing ibutamoren are unapproved drugs 7.

MK-677's Legacy in GH Secretagogue Science

Despite never reaching market, MK-677 left a permanent mark on endocrinology. The Merck receptor-cloning work that used MK-677 as a probe directly enabled the 1999 discovery of ghrelin by Kojima and Kangawa. Without the synthetic ligand, the receptor might have remained orphan for years longer.

MK-677 also demonstrated that oral GH secretagogues could maintain pulsatile GH physiology, a principle that distinguishes secretagogues from exogenous GH injection. Every subsequent oral GH secretagogue candidate, including anamorelin (approved in Japan for cancer cachexia), built on the pharmacological framework Merck established with MK-677 8.

The ghrelin receptor itself became a major drug target beyond GH. Relamorelin (for gastroparesis) and other GHS-R1a agonists in clinical development owe their mechanistic rationale to the receptor biology first characterized using MK-677 as the index compound.

Current Status and Clinical Relevance

MK-677 is not approved by the FDA, EMA, or any major regulatory agency for any indication. It has no established therapeutic use. Clinicians cannot legally prescribe it as a finished pharmaceutical product in the United States.

The compound circulates widely on gray-market research chemical sites. The FDA's Office of Criminal Investigations has issued multiple warning letters to companies selling ibutamoren as a supplement or "for research purposes only" 7. Purity, dosing accuracy, and contamination risk in these products are unregulated.

Patients who ask about MK-677 should be counseled on three points. The GH and IGF-1 raising effects are well-documented in controlled trials. The insulin resistance risk is consistent across studies and may be clinically significant in patients with metabolic syndrome or prediabetes. And the compound has no regulatory oversight, meaning any product purchased carries unknown quality risk.

For patients with documented adult GH deficiency, FDA-approved recombinant GH and the oral GH secretagogue macimorelin (approved as a diagnostic agent) remain the evidence-based options 9. MK-677 remains, as it has been for three decades, a research tool that reshaped how scientists understand ghrelin biology and pituitary GH control.